S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Discover Lexagene - Open to Accredited Investors Only (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Discover Lexagene - Open to Accredited Investors Only (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Discover Lexagene - Open to Accredited Investors Only (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
New Bitcoin Projection: $165,000 in the Next 18 Months (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Discover Lexagene - Open to Accredited Investors Only (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:FATE

Fate Therapeutics (FATE) Stock Price, News & Analysis

$6.96
+0.08 (+1.16%)
(As of 02/23/2024 ET)
Today's Range
$6.75
$7.11
50-Day Range
$3.06
$7.56
52-Week Range
$1.63
$7.74
Volume
1.54 million shs
Average Volume
3.05 million shs
Market Capitalization
$686.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25

Fate Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
10.2% Downside
$6.25 Price Target
Short Interest
Bearish
12.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.16mentions of Fate Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$199,732 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.78) to ($2.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.83 out of 5 stars

Medical Sector

652nd out of 940 stocks

Biological Products, Except Diagnostic Industry

112th out of 158 stocks


FATE stock logo

About Fate Therapeutics Stock (NASDAQ:FATE)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Stock Price History

FATE Stock News Headlines

A Preview Of Fate Therapeutics's Earnings
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
FATE Mar 2024 5.000 put
FATE Mar 2024 7.500 put
Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Update
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Fate Therapeutics, Inc.
Germany retail sales drop 1.6% in December
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
2/23/2024
Next Earnings (Confirmed)
2/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
551
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.25
High Stock Price Target
$10.00
Low Stock Price Target
$3.00
Potential Upside/Downside
-10.2%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

Net Income
$-281,720,000.00
Net Margins
-163.04%
Pretax Margin
-163.04%

Debt

Sales & Book Value

Annual Sales
$96.30 million
Book Value
$4.98 per share

Miscellaneous

Free Float
93,632,000
Market Cap
$686.26 million
Optionable
Optionable
Beta
1.65
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report














FATE Stock Analysis - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price target for 2024?

10 Wall Street research analysts have issued twelve-month target prices for Fate Therapeutics' shares. Their FATE share price targets range from $3.00 to $10.00. On average, they expect the company's share price to reach $6.25 in the next twelve months. This suggests that the stock has a possible downside of 10.2%.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2024?

Fate Therapeutics' stock was trading at $3.74 at the beginning of 2024. Since then, FATE stock has increased by 86.1% and is now trading at $6.96.
View the best growth stocks for 2024 here
.

Are investors shorting Fate Therapeutics?

Fate Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totaling 11,480,000 shares, an increase of 6.6% from the January 15th total of 10,770,000 shares. Based on an average daily trading volume, of 2,440,000 shares, the days-to-cover ratio is presently 4.7 days. Approximately 12.4% of the shares of the company are short sold.
View Fate Therapeutics' Short Interest
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our FATE earnings forecast
.

How can I listen to Fate Therapeutics' earnings call?

Fate Therapeutics will be holding an earnings conference call on Monday, February 26th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) posted its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.04. The biopharmaceutical company earned $0.93 million during the quarter, compared to analysts' expectations of $5.41 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 38.44% and a negative net margin of 163.04%. The business's revenue for the quarter was down 95.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.79) earnings per share.

What ETF holds Fate Therapeutics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.43%), Point72 Asset Management L.P. (3.54%), Monaco Asset Management SAM (2.21%), Federated Hermes Inc. (1.88%), Vestal Point Capital LP (1.31%) and Charles Schwab Investment Management Inc. (1.00%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FATE) was last updated on 2/24/2024 by MarketBeat.com Staff